Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells

Cancer Research

Volumn 69, Issue 8, 2009, Pages 3510-3519

  Ivanov, Vladimir N ^a,b   Zhou, Hongning ^a   Partridge, Michael A ^a   Hei, Tom K ^a,b  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ATM PROTEIN; CASPASE 8 INHIBITOR; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SERINE DERIVATIVE; STAT3 PROTEIN; TYROSINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GAMMA IRRADIATION; GENE REPRESSION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANIMALS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HUMANS; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; MORPHOLINES; NF-KAPPA B; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PYRONES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65949119339     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3883     Document Type: Article

References (48)

1. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 2006; 31: 402-10. (Pubitemid 44038916)
2. Barlow C, Hirotsune S, Paylor R. et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996; 86: 159-71. (Pubitemid 26259926)
3. Matsuoka S, Ballif BA, Smogorzewska A. et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316: 1160-6. (Pubitemid 46877472)
4. Wu ZH, Shi Y, Tibbetts RS, Miyamoto S. Molecular linkage between the kinase ATM and NF-κB signaling in response to genotoxic stimuli Science 2006; 311: 1141-6. (Pubitemid 43305951)
5. Bhoumik A, Takahashi S, Breitweiser W, Shiloh Y, Jones N, Ronai Z, ATM-dependent phosphorylation of ATF2 is required for the DNA damage response. Mol. Cell 2005; 18: 577-87. (Pubitemid 40726234)
6. Zhang Y, Cho YY, Petersen BL, Bode AM, Zhu F, Dong Z. Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3. J. Biol. Chem 2003; 278: 12650-9. (Pubitemid 36800025)
7. Perils C, Herlyn M. Recent advances in melanoma biology. Oncologist 2004; 9: 182-7. (Pubitemid 38452117)
8. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002; 2: 420-30. (Pubitemid 37328939)
9. Schaefer U, Voloshanenko O, Willen D, Walczak H. TRAIL: a multifunctional cytokine. Front Biosci 2007: 12: 3813-24.
10. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest 2008; 118: 1979-90.
11. Chinnaiyan AM, Prasad U, Shankar S. et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. U S A 2000; 97; 1754-9. (Pubitemid 30118515)
12. Ivanov VN, Zhou H, Hei TK. Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res 2007; 67: 5397-407. (Pubitemid 46997280)
13. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L /TRAIL). J. Clin. Oncol 2008; 26: 3621-30.
14. Satyamoorthy K, DeJesus E, Linnenbach AJ. et al. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 1997; 7 Suppl 2: S35-42. (Pubitemid 27501624)
15. van Dam H, Huguier S, Kooistra K. et al. Autocrine growth and anchorage Independence: two complementing jun-controlled genetic programs of cellular transformation. Genes Dev 1998; 12: 1227-39. (Pubitemid 28194057)
16. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequencespecific DNA-binding site. Oncogene 2000; 19: 1735-43. (Pubitemid 30200979)
17. Bartke T, Siegmund D, Peters N. et al. p53 upregulates cFLIP, inhibits transcription of NF-κB-regulated genes
18. and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 2001; 20: 571-80.
19. Ricci MS, Jin Z, Dews M. et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell Biol. 2004; 24: 8541-55. (Pubitemid 39245075)
20. Resnick-Silverman L, St Clair S, Maurer M, Zhao K, Manfredi JJ.. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev 1998; 12: 2102-7. (Pubitemid 28348033)
21. Biton S, Dar I, Mittelman L, Pereg Y, Barzilai A, Shiloh Y. Nuclear ataxia-telangiectasia mutated (ATM) mediates the cellular response to DNA double strand breaks in human neuron-like cells. J. Biol. Chem 2006; 281: 17482-91. (Pubitemid 43909556)
22. Ivanov VN, Hei TK. Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor α- mediated pathway, J. Biol. Chem 2004; 279: 22747-58. (Pubitemid 38679475)
23. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499-506. (Pubitemid 36168436)
24. Hirao A, Kong YY, Matsuoka S. et al. DNA damageinduced activation of p53 by the checkpoint kinase Chk2. Science 2000; 287: 1824-7. (Pubitemid 30143967)
25. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, Hei TK Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res 2008; 314: 1163-76.
26. Thayaparasingham B, Kunz A, Peters N, Kulms D. Sensitization of melanoma cells to TRAIL by UVB- induced and NF-κB-mediated downregulation of XIAP. Oncogene 12009; 28: 345-62.
27. Ivanov VN, Hei TK. Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. Exp Cell Res 2006; 312: 4120-38.
28. Amundson SA, Do KT, Vinikoor LC. et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 2008; 68: 415-24.
29. Rashi-Elkeles S, Elkon R, Weizman N. et al. Parallel induction of ATM-dependent pro- and antiapoptotic signals in response to ionizing radiation in murine lymphoid tissue. Oncogene 2006; 25: 1584-92. (Pubitemid 43361943)
30. Hickson I, Zhao Y, Richardson CJ. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004; 64: 9152-9. (Pubitemid 39665530)
31. 2/M arrest and apoptosis via a novel p53-dependent pathway in NB4 promyelocytic leukemia cells. J. Cell Physiol 2003; 196: 276-83. (Pubitemid 36775874)
32. Shetty S, Graham BA, Brown JG. et al. Transcription factor NF-κB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol. Cell Biol. 2005; 25: 5404-16. (Pubitemid 40853578)
33. Ravi R, Bedi GC, Engstrom LW. et al. Regulation of death receptor expression and 'TRAIL/Apo2L-induced apoptosis by NF-κB. Nat Cell Biol. 2001; 3: 409-16. (Pubitemid 32288449)
34. Higuchi H, Grambihler A, Canbay A, Bronk SF, Gores GJ. Bile acids up-regulate death receptor 5/TRAIL- receptor 2 expression via a c-Jun. N-terminal kinasedependent pathway involving Spl. J. Biol. Chem 2004; 279: 51-60. (Pubitemid 38044798)
35. Wen Z, Zhong Z, Darnell JE, Jr. Maximal activation of transcription by Statl and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995; 82: 241-50.
36. Kusaba M, Nakao K, Goto T. et al. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J. Hepatol 2007; 47: 546-55. (Pubitemid 47331746)
37. Meng RD, El-Deiry WS. p53-independent up-regulation of KILLER/DR5 TRAR. receptor expression by glucocorticoids and interferon-γ. Exp Cell Res 2001; 262: 154-69. (Pubitemid 32980255)
38. Ivanov VN, Bhoumik A, Krasilnikov M. et al. Cooperation between STAT3 and c-Jun. suppresses Fas transcription. Mol. Cell 2001; 7: 517-28. (Pubitemid 32706344)
39. Ivanov VN, Krasilnikov M, Ronai Z. Regulation of Fas expression by STAT3 and c-jun is mediated by phosphatidylinositol 3~kinase~AKT signaling. J. Biol. Chem 2002; 277: 4932-44.
40. Truman JP, Gueven N, Lavin M. et al. Downregulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis. J. Biol. Chem 2005; 280: 23262-72. (Pubitemid 40853238)
41. Rainey MD, Charlton ME, Stanton RV, Kastan MB. Transient inhibition of ATM kinase Is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res 2008; 68: 7466-74.
42. O'Connor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the Inhibition of DNA strand break repair. Oncogene 2007; 26: 7816-24. (Pubitemid 350242461)
43. Leslie K, Lang C, Devgan G. et al. Cyclin Dl is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 2006; 66: 2544-52.
44. Niu G, Wright KL, Ma Y. et al. Role of Stat3 in regulating p53 expression and function. Mol. Cell Biol. 2005; 25: 7432-40. (Pubitemid 41170107)
45. Tsukahara T, Kannagi M, Ohashi T. et al. Induction of Bcl-x (L) expression by human T-cell leukemia virus type 1 Tax through NF-κB in apoptosis-resistant T-cell transfectants with Tax. J. Virol 1999; 73: 7981-7. (Pubitemid 29441656)
46. Catlett-Falcone R, Landowski TH, Oshiro MM. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-15. (Pubitemid 29077388)
47. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 5: 798-811. (Pubitemid 44187627)
48. Haga S, Terui K, Zhang HQ. et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J. Clin. Invest 2003; 112: 989-98. (Pubitemid 38056314)